Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?

Background: Afatinib can be started at a dose lower than the recommended starting dose of 40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), however treatment outcomes in real-world clinical practice remains unclear. Methods: This retro...

Full description

Bibliographic Details

Main Authors:	Mau, Ern Poh, Chai, Chee Shee, Chong, Kin Liam, Go, Fuang Ho, Yong, Kek Pang, Harissa, Husainy Hasbullah, Lye, Mun Tho, Ibtisam, Muhamad Nor, Kean, Fatt Ho, Muthukkumaran, Thiagarajan, Azlina, Samsudin, Azza, Omar, Choo, Khoon Ong, Sing, Yang Soon, Sin, Nee Tan, Soon, Hin How
Format:	Article
Language:	en
Published:	AME Publishing Company 2024
Subjects:	R Medicine (General) RC0254 Neoplasms. Tumors. Oncology (including Cancer) RZ Other systems of medicine
Online Access:	http://ir.unimas.my/id/eprint/44420/3/Does%20dose.pdf http://ir.unimas.my/id/eprint/44420/ https://tlcr.amegroups.org/article/view/83673/html https://dx.doi.org/10.21037/tlcr-23-691
Tags:	Add Tag No Tags, Be the first to tag this record!